Market Closed

PTGX
Protagonist Therapeutics
$ 130.95
-2.55%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago

Protagonist Therapeutics News

Latest Protagonist Therapeutics Stock News & PTGX Headlines

Protagonist Therapeutics (PTGX) Q3 Earnings and Revenues Surpass Estimates
10 days ago | zacks.com
Protagonist Therapeutics (PTGX) to Report Q3 Results: Wall Street Expects Earnings Growth
17 days ago | zacks.com
Why Protagonist Therapeutics (PTGX) is a Top Momentum Stock for the Long-Term
17 days ago | zacks.com
Wall Street Analysts See a 25.34% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
18 days ago | zacks.com
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
22 days ago | seekingalpha.com
Protagonist Therapeutics (PTGX) Upgraded to Strong Buy: Here's What You Should Know
a month ago | zacks.com
Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head Review
2 months ago | defenseworld.net
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $9,289,446.64 in Stock
2 months ago | defenseworld.net
Protagonist Therapeutics (NASDAQ:PTGX) CEO Sells $7,902,361.38 in Stock
2 months ago | defenseworld.net
Hsbc Holdings PLC Purchases 24,045 Shares of Protagonist Therapeutics, Inc. $PTGX
2 months ago | defenseworld.net
Load More

Download App

Keep track of your holdings and explore over 40,000 cryptocurrencies

oinCodex Android App
CoinCodex Mobile App
Market Closed

PTGX
Protagonist Therapeutics
$ 130.95
-2.55%   Last 24H
 
Trading with leverage comes with a high risk and may not be suitable for everyone.
   
Trading with leverage comes with a high risk and may not be suitable for everyone.
Portfolio
Updated 2 days ago